News

Takeda’ investigational compound, TAK-536 has entered into phase-III clinical trials in Japan. TAK-536 is a novel angiotensin receptor blocker (ARB) that is meant to lower blood pressure by

GlaxoSmithKline (GSK) and Chroma Therapeutics have signed a collaboration agreement to develop macrophage-targeted compounds, using Chroma’ proprietary esterase-sensitive motif (ESM) technology. Chroma would undertake four discovery and development

Baxter has signed a definitive agreement with Edwards Lifesciences to acquire certain assets related to Edwards’ hemofiltration product line, also known as Continuous Renal Replacement Therapy (CRRT). The

YM BioSciences’ licensee for nimotuzumab, Daiichi-Sankyo has initiated the enrollment of a phase II trial. It is to evaluate nimotuzumab, in combination with radiation therapy/cisplatin/vinorelbine, in first-line curative

Resolvyx has initiated the first human phase-I clinical trial, evaluating an oral resolvin therapeutic, RX-10001 in healthy volunteers. RX-10001 is a synthetic form of RvE1, a naturally occurring

Cerulean has signed a worldwide license agreement with Calando Pharma, a subsidiary of Arrowhead Research Corporation. Under the agreement, Cerulean has acquired worldwide rights to Calando’ proprietary cyclodextrin

OctoPlus has started pharmaceutical production in its new manufacturing facility in Leiden. The facility has received a license from the Dutch authorities to manufacture pharmaceutical products, according to

Spherix has received its first full-scale production batch of cGMP (FDA Current Good Manufacturing Practice) D-tagatose, USP grade. Spherix will use the tagatose in the process of satisfying

Osiris has reported six-month interim data from phase-II clinical trial, evaluating Prochymal for the treatment of chronic obstructive pulmonary disease (COPD). In the placebo-controlled study, 62 patients were